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I. INTRODUCTION 
 
  
1. NEUROIMMUNOMODULATION 
The term neuroimmunomodulation has been coined to define the interaction between the neural and 
neuroendocrine system and the immune system. For a long time the immune system was considered to be 
independent and self-regulatory even if the existence of a link between the nervous and the immune systems 
was already postulated early this century. In 1903 Sajous1 suggested that the thymus gland functions as an 
endocrine organ, and that various thymic peptides may modulate lymphocyte function directly and/or 
influence the immune system via hormonal and neural pathways. Consistently, in 1910 Ott and Scott2 
reported that thymic extracts induced milk ejection in the goat, an action that is actually known to be 
mediated by the neurohypophysal peptide oxitocin. This was the first evidence that a non-nervous organ 
could have “nervous” function. Much later, in 1985,Roszman et al.3,4 demonstrated that lesions in the 
central nervous system (CNS) could influence the immune system. In particular Roszman showed that 
lesions of the hypothalamus resulted in a decreased number of nucleated spleen cells and thymocytes. 
These two evidences strongly suggested the existence of a bidirectional, reciprocal communication between 
the immune systems and the central nervous system. Here, I will briefly review the current evidence in this 
rapidly growing field of research. 
 
1.1 Neural and hormonal factors that affect hematopoiesis 
 
Sympathetic system and catecholamines 
In 1983 Besedovsky et al.5, showed that CNS functions were affected during the immune response. This 
group measured a decrease of norepinephrine (NE) level in the hypothalamus 4 days after immunization with 
a T-dependent antigen, suggesting that activation of the immune system directly modulates the CNS activity. 
Another demonstration of a link between the nervous and the immune system may be found in the studies of 
Felten et al.6 which showed the presence of a direct innervation of lymphoid tissues. Such innervation is 
dense as many fibers enter the lymphoid tissues, and bi-directional, because of the presence of various 
innervation types (noradrenergic, cholinergic, peptidergic) and of different origin (for example the mouse tibia 
receive fibers from two sources, sympathetic fibers from the femoral artery/vein and other fibers from the 
sciatic nerve7,8) suggesting the presence of both afferent and efferent nerve supply. Not only nerve fibers 
enter the lymphoid organs but it has been reported that lymphocytes and other blood cells present specific 
receptors for catecholamines.9,10 This suggests that the innervation entering the bone marrow (BM) acts not 
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only on blood vessels but also on hematopoietic cells. Moreover it has been reported that also lymphoid cells 
produce catecholamines (their complete metabolic pathway was detected) and that catecholamines may 
affect the functions of such cells.11,12 Taken together, these findings reveal the existence of a complex and 
finely tuned network between the immune and the nervous systems. 
 
Neuropeptides 
Among the peptidergic mechanisms which may affect the immune machinery, substance P (SP) seems to 
play an important role. SP is an 11 amino acid neuropeptide first identified in 1931 by its capacity to induce 
contraction of guinea pig ileum.13 During the following decades, its role has been studied extensively. SP 
was described to be released from nerve ending and to elicit diverse biological activities (Table. 1). SP has 
been reported to influence lymphocyte and monocyte metabolism. First of all, SP was reported to stimulate 
chemotaxis of human and guinea pig monocytes in vitro with an EC50 value of approximately 0.1 pM.14 The 
chemotactic effect of SP could be blocked by D-amino acid analogs of SP but not by antagonists of the 
chemotactic peptide N-formyl-methionyl-leucyl-phenylalanine (FMLP), suggesting SP specificity. SP elicits 
not only mononuclear leukocyte chemotaxis but also generation of newly synthesized inflammatory 
mediators from macrophages activated by bacteria (i.e. nitric oxide).15 
 
Action Target tissue 
Smooth muscle contraction Intestines, pulmonary airways 
Vasodilatation Systemic arterioles 
Vasoconstriction Cerebral arteries 
Increased microvascular permeability Skin 
Increased secretion Salivary glands, tracheal epithelium, nasal epithelium 
Table 1: Direct effect of SP on non-neural tissues 
Several other macrophage responses are also evoked by SP, including the down-regulation of membrane-
associated enzymes and the release of inflammatory products derived from the lipoxygenase and 
cyclooxygenase pathways.15,16 Furthermore, SP can also enhance immune functions by regulating the 
production of cytokines from macrophages. Studies with human blood monocytes have shown that 
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nanomolar (nM) concentration of SP can stimulate the production of interleukin-1 (IL-1), tumor necrosis 
factor (TNF-α), and interleukin-6 (IL-6).17,18 
As SP, other molecules that are normally related to nerve activation like vasoactive intestinal peptide (VIP, a 
28 amino acids peptide) have been reported to modulate BMfunction. VIP was first isolated from intestinal 
extracts and identified as an hormone on the basis of its vasodilatatory effects.19 Then it was recognized as 
a neurotransmitter and has been implicated in a great variety of biological processes as reported in table 2.20,21 
 
Target/function Effect of VIP 
Monocytes VIP modulate monocyte migration22 
Mast cells VIP stimulates histamine release in human skin mast cells23 
lymphocytes in vitro 
Mitogen responses VIP inhibits the response of PBM to mercuric chloride
24 
VIP inhibits the response of murine lymphocytes to Con-A and soluble egg 
antigens (SEA)25 
Mixed-lymphocyte 
reaction VIP inhibits murine one-way MLR
26 
Immunoglobulin 
prodction VIP inhibits response of PBM to pokeweed mitogen
27 
VIP inhibits Ig production in Con-A stimulated murine lymphocyte cultures28 
lymphokine production VIP inhibits production of IL-2 in Con-A stimulated murine lymphocyte 
cultures29 
LGL activity VIP inhibits NK activity in PBM30 
lymphocytes in vivo VIP infusion inhibits the output of lymphocytes from sheep lymph nodes31 
Decreased expression of VIP receptor on murine T cells decreases the rate of 
migration of the cells into Peyer’s patches and mesenteric nodes32 
Table 2: Modulation of lymphoid cell functions by Vasoactive Intestinal Peptide: VIP: Vasoactive Intestinal 
Peptide, PBM: Peripheral Blood Mononuclear cells, NK: Natural Killer cells, MLR: Mixed 
lymphocytes Reaction 
 
Melatonin 
Already in 1973 Deguchi et al. reported that the pineal neurohormone melatonin is able to synchronizes the 
organism with the photoperiod.33,34 In the following years, it has been reported that melatonin plays also an 
immunomodulatory role.35 In particular it modulates the antibody response. This role is now well recognized. 
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It has been reported that T-helper cells bear G-protein coupled melatonin receptors and, perhaps, melatonin 
nuclear receptors.36 In addition to the modulation of antibody production, activation of melatonin receptors 
enhances the release of T-helper cell type 1 (Th1) cytokines, such as IFN-γ and IL-2, as well as of novel 
opioid cytokines which crossreact immunologically with both interleukin-4 (IL-4) and dynorphin B.37-39 
Melatonin has also been reported to enhance the production of IL-6 from human monocytes. These 
mediators may counteract secondary immunodeficiencies, protect mice against lethal viral and bacterial 
diseases, synergize with IL-2 in cancer patients and influence hematopoiesis.40 Hematopoiesis is apparently 
influenced by the action of the melatonin-induced opioids on kappa-opioid receptors present on stromal 
BMcells. Most interestingly, IFN-γ and CSF may modulate the production of melatonin in the pineal gland. A 
hypothetical pineal-immune-hematopoietic network is, therefore, taking shape. In conclusion, melatonin 
seems to be an important immunomodulatory hormone which deserves to be further studied, in order to 
identify its relevance in immune-based diseases, its therapeutic indications, and its adverse effects. 
 
Other neural and hormonal factors 
Several other neural or hormonal substances has been reported to affect hematopoiesis. Sexual hormones 
increases the immune reactivity in female; glucocorticoids and growth hormone are fundamental in thymus 
and T cell development. Enkephalins and Endorphins can either stimulate or suppress immune function 
depending on the doses. 
 
 
After this short overview of the different effects of neural and hormonal substances on the immune-
hematopoietic system one can clearly appreciate the complexity of the network between these two systems. 
Moreover it can be inferred that only a fine regulation of the interaction between these systems may result in 
a correct functionality of both systems. Therefore, lack of a basic neural, hormonal or immune factors might 
cause or be associated to disease states. In addition, a wrong balance between neural, hormonal and 
immune factors may be involved in a series of immuno-based or hematopoietic diseases. The relevance of a 
complete understanding of this complex network seems therefore evident. This might allows therapeutic 
approaches based on the balancing or replacement of two or more endogenous substances and not (as it 
appears today) by “inserting” exogenous and foreign substances, with the risk of adverse secondary effects. 
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1.2 Cytokines 
The old adage “don’t judge a book by its cover” is certainly true when applied to cytokines. Although 
cytokines were originally defined as host defense proteins, they clearly have many other functions. 
Historically, humoral factors which regulate lymphocytes and were contained in the supernatant of mitogen- 
or allogeneic cell-stimulated lymphocytes were called lymphokines. On the other side factors of the same 
nature but regulating monocytes and macrophages were called monokines. The specific name of such 
substances was composed by the name of the target cell followed by the biological activity of the factor. For 
example a factor that stimulates T-cell proliferation would be named T-cell growth factor (TCGF). The 
discovery of tumour-cell lines on one side, and of lymphokine-dependent-cell lines on the other side, 
provided a method for obtaining cytokines in great amount, and in the same time a good method for testing 
their activities. With these methods it became clear that differently named lymphokines were just 
representing different activities  of the same factor. Later a standardized nomenclature was developed, and 
the factors were called “Interleukines”, for their activity of signaling between leukocytes. Then cytokines was 
used in general to define both lymphokines and monokines. The first interleukin, IL-1, was shown to be 
responsible of the activity of at least eight of the previously reported factors. More recently, recombinant DNA 
techniques, allowed the purification and identification of the cytokines which are listed in table 3. In this table 
a series of cytokines, called colony stimulating factors (CSF), is skipped. CSF are a family of acidic 
glycoproteins, named after their ability to stimulate growth and differentiation of distinct hematopoietic cell 
lineages. Four distinct CSF have been identified: multilineage CSF (multi CSF), that correspond to IL-3; 
granulocyte-macrophage CSF (GM-CSF); macrophage CSF (M-CSF); granulocyte CSF (G-CSF). As 
suggested by the name, these substances stimulate the growth of specific lineages, and, with interleukins, 
participate in the balancing of the hematopoietic system. As neural and hormonal factors, it seems clear that, 
cytokines have effects not only on the immune system, but also on other systems (tab 3). For example, IL-1 
acts on the hypothalamus, IL-11 on hepatocytes, or IL-15 on the intestinal epithelium. Moreover, it seems 
clear that it is not the production or secretion of one of these molecules that regulates a given function, but 
that it is the balance between two or more of these molecules that matters. 
In the last years, some evidence of the modulation of production of interleukines by neural factors has been 
reported. Huang et al. stimulated IL-6 production in lymphocytes by injecting rat with IL-1. They then 
demonstrated that NE in the dose range of 10-6-10-4 M increased IL-6 levels in the supernatant  of spleen 
lymphocytes obtained from rats treated with NE. In addition NE at doses 10-9-10-7 M enhanced the effects of 
IL-1 on IL-6 release by spleen lymphocytes. This seems an important point to understand another level of the 
interaction between the nervous and immune system. In most cases, substances that act on one of the two 
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systems have a specific effect at one concentration and the opposite effect at other concentration (higher or 
lower). This is the case, for example, in the growth-factor-based treatment during chemoterapy. In fact the 
properties of such substances are responsible for the serious negative side effects.41 
This again suggests that what is needed for a correct functioning of both the nervous and immune system is 
a fine regulation of their interaction. This interaction is further complicated by the complexity of the immune 
system which may be divided as follows: 
• T and B lymphocytes 
• Accessory non-lymphoid cells (epithelial cells, dendritic cells, macrophages and so forth) 
• Hormones, released at remote site and entering the immune micromilieu via the blood 
• Cholinergic, adrenergic, peptidergic and other neurons 
• biologically active substances, such as Interleukins, neuropeptides 
The fine interaction and interdependence of these components results also in the possibility for a component 
to counterbalance, at least in part, the possible lack of other components. 
 
  Major biological function 
Cytokine Secreted by Target cells / tissue Activity 
Interleukin-1 
(IL-1α, IL-1β) 
Monocytes, 
macrophages, B 
cells, dendritic 
cells and other 
TH cells 
B cells 
 
NK cells 
Vascular endothelial cells 
Macrophages and 
neutrophiles 
Hepatocytes 
 
Hypothalamus 
Co-stimulates activation 
Promotes maturation and clonal 
expansion 
Enhances activity 
Increases expression of ICAMs 
Chemotactic activity 
 
Induces synthesis of acute-phase 
proteins 
Induces fever 
Interleukin-2 
(IL-2) 
TH1 cells Antigen-primed TH and TC 
cells 
Antigen-specific T-cell clones
NK cells (some) and TC cells 
Induces proliferation 
 
Supports long term growth 
Enhances activity 
Interleukin-3 
(IL-3) 
TH cells, NK 
cells, and mast 
cells 
Hematopoietic cells 
Mast cells 
Supports growth and differentiation 
Stimulates growth and histamine 
secretion 
Interleukin-4 
(IL-4) 
TH2 cells, mast 
cells, NK cells 
Antigen-primed B cells 
Activated B cells 
 
 
Resting B cells 
Thymocytes and T cells 
Macrophages 
 
Mast cells 
Co-stimulates activation 
Stimulates proliferation and 
differentiation; induces class switch to 
IgG1 and IgE 
Up-regulates class II MHC expression 
Induces proliferation 
Up-regulates class II MHC expression; 
increases phagocytic activity 
Stimulates growth 
Interleukin-5 
(IL-5) 
TH2 cells, mast 
cells 
Activated B cells 
 
 
Eosinophils 
Stimulates proliferation and 
differentiation; induces class switch to 
IgA 
Promotes growth and differentiation 
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  Major biological function 
Cytokine Secreted by Target cells / tissue Activity 
Interleukin-6 
(IL-6) 
Monocytes, 
macrophages, 
TH2 cells, bone -
marrow stromal 
cells 
Proliferating B cells 
 
Plasma cells 
Myeloid stem cells 
Hepatocytes 
Promotes terminal differentiation into 
plasma cells 
Stimulates antibody secretion 
Help in differentiation promotion 
Induces synthesis of acute-phase 
proteins 
Interleukin-7 
(IL-7) 
Bone-marrow, 
thymic stromal 
cells 
lymphoid stem cells 
 
Resting T cells 
Induces differentiation into progenitor B 
and T cells 
Increases expression of IL-2 and its 
receptor 
Interleukin-8 
(IL-8) 
Macrophages, 
endothelial cells 
Neutrophils Chemokine; chemotactic activity; 
induces adherence to vascular 
endothelium and extravasation into 
tissue 
Interleukin-9 
(IL-9) 
TH cells Some TH cells Acts as mitogen, supporting proliferation 
in absence of antigen 
Interleukin-10 
(IL-10) 
TH2 cells Macrophages 
 
 
Antigen-presenting cells 
Suppresses cytokine production and 
thus indirectly reduces cytokine 
production by TH1 cells 
Down-regulates class II MHC 
expression 
 
Interleukin-11 
(IL-11) 
Bone-marrow 
stromal cells 
Plasmocytomas 
Progenitor B cells 
Megakaryocytes 
Hepatocytes 
Supports growth 
Promotes differentiation 
Promotes differentiation 
Induces synthesis of acute-phase 
proteins 
Interleukin-12 
(IL-12) 
Macrophages, B 
cells 
Activated TC cells 
 
NK and LAK cells and 
activated TH1 cells 
Acts synergistically with IL-2 to induces 
differentiation into CTLs 
Stimulates proliferation 
Interleukin-13 
(IL-13) 
TH cells Macrophages Inhibits activation and release of 
inflammatory cytokines; important 
regulator of inflammatory response 
Interleukin-15 
(IL-15) 
T cells T cells, intestinal epithelium 
 
NK 
Activated B cells 
Stimulates growth of intestinal 
epithelium, T cell proliferation 
Support proliferation 
Co-mitogen for proliferation and 
differentiation 
Interleukin-16 
(IL-16) 
T cells (primarily 
CD8+) 
Eosinophils 
CD4+ T cells 
 
 
 
Monocytes 
Eosinophils 
Chemotaxis; induces expression of 
class II MHC; induces synthesis of 
cytokines; suppresses antigen-induced 
proliferation 
Chemotaxis; induces class II MHC 
Chemotaxis; induces cell adhesion 
Interferon alpha 
(IFN-α) 
Leukocytes Uninfected cells Inhibits viral replication 
Interferon beta 
(IFN-β) 
Fibroblast Uninfected cells Inhibits viral replication 
8 
  
 
  Major biological function 
Cytokine Secreted by Target cells / tissue Activity 
Interferon 
gamma 
(IFN-γ) 
TH1, Tc, NK cells Uninfected cells, 
Macrophages 
Many cell types 
 
Proliferating B cells 
Inhibits viral replication 
Enhances activity 
Increases expression of class I and 
class II MHC molecules 
Induces class switch to IgG2a; 
blocks IL-4-induced class switch to IgE 
and IgG1 
Transforming 
growth factor β 
(TGF-β) 
Platelets, 
macrophages, 
lymphocytes, 
mast cells 
Monocytes and 
macrophages 
Activated macrophages 
Epithelial, endothelial, 
lymphoid, and 
hematopoietic cells 
Proliferating B cells 
Chemotactically attracts 
 
Induces increased IL-1 production 
Inhibits proliferation, thus limiting 
inflammatory response and promoting 
wound healing 
Induces class switch to IgA 
Tumor necrosis 
factor α (TNF-α) 
Macrophages, 
mast cells 
Tumor cells 
Inflammatory cells 
Has cytotoxic effect 
Induces cytokine secretion and is 
responsible for extensive weight loss 
(cachexia) associated with chronic 
inflammation 
Tumor necrosis 
factor β (TNF-β) 
TH1 and Tc cells Tumor cells 
 
Macrophages and 
neutrophils 
Has cytotoxic and other effects similar 
to TNF-α 
Enhances phagocytic activity 
 
Table 3: Cytokines which are involved in the complex network regulating the development of cellular and 
humoral immune response, induction of the inflammatory response, hematopoiesis and cellular 
proliferation and differentiation. Cytokines act not only on hematopoietic cells, but also on 
hepatocytes, vascular endothelial cells, and last but not least on cells of the nervous system. 
 
 
 
1.3 HEMATOPOIESIS 
1.3.1 lymphoid organs 
In 1868, Ernst Neuman recognized that cells of the immune system and blood cells require continuous 
replenishment during postnatal life. Neuman also recognized that this process occurred within the primary 
lymphoid organs (BM and thymus). 
 
a) Bones are composed of cortex and medulla. The cortex is a strong layer of compact bone; the medulla is 
a honeycomb of spongy bone, the interstices of which are known as the medullary cavity and contain the 
marrow. BM is either red marrow containing hematopoietic cells or yellow marrow which is largely 
adipose tissue. The distribution of hematopoietic marrow is dependent on age, decreasing with age. 
Moreover, in response to demand, the volume of the marrow cavity occupied by hematopoietic tissue 
expands. 
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b) On the other side, the thymus is an organ situated in the superior mediastinum, anterior to the great 
vessels as they emerge from the heart. It consist of two lobes, arising in the embryo as separate 
primordia on each side of the midline, but later becoming closely joined by connective tissue. The thymus 
attains its greatest relative weight at the end of fetal live, but its absolute weight continues to increase till 
the puberty. It then begins to undergo an involution which progresses rapidly until the organ becomes 
largely replaced by adipose cells in the adult. 
 
Cells of the immune system are organized in tissues that are called lymphoid system and contain less or 
more mature lymphocytes. 
Lymphopoiesis take place almost entirely in primary lymphoid organs, where stem cell grow and differentiate 
into specialized lymphocyte. Only T lymphocyte escape from BM to thymus for differentiating. In bird B cells 
differentiate in a specialized organ call bursa of Fabricius. Moreover, in primary lymphoid organs 
lymphocytes acquire the capacity for distinguishing within self and non-self antigens. 
 
After leaving these organs, cells circulate in the blood until they reach one of the secondary lymphoid organs, 
such as lymph nodes, spleen and tonsils. They then exit the bloodstream through specialized blood vessels 
called high endothelial venules. Although the lymphocytes become rather tightly packed (each gram of lymph 
node contains a billion of them), they can still move about freely. Consequently, the nodes are excellent sites 
for lymphocytes to become activated by antigen and antigen-presenting cells entering through the afferent 
lymphatic vessel. 
 
All the lymphoid organs and tissues collaborate directly or indirectly to maintain the blood composition, and 
to build up the imunological defense. 
10 
  
 
 
Figure 1: Disposition in the body of primary and secondary lymphoid organs. (from 
IMMUNOLOGY, second edition, Janis Kuby, Freeman eds)1.3.2 Bone marrow cells 
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Only a small population of stem cells is needed to generate large and different populations of maturing cells. 
This remarkable phenomenon takes place in the BM. In fact, pluripotent (or multipotent) stem cells are 
capable of regenerating themselves (self renewal) and, secondly, of generating all types of hematopoietic 
cells. This process is necessary to maintain the steady state in which the production of mature blood cells 
equals their loss (principally by cell aging). For example the average erythrocyte has a life span of 120 days 
before it is phagocytosed and digested by macrophages in the spleen. The various white blood cells have a 
life span ranging from days for neutrophils to as long as 20-30 years for some T lymphocytes. To maintain a 
steady-state level, the average human must produce an estimated 3.7 x 1011 cells per day. To better 
understand this mechanism it is important to define the different components of the primary lymphoid organs 
(BM and thymus) in which hematopoiesis takes place. 
 
 
1.3.2.1 Stroma cells 
The hematopoietic cells of the BM are embedded in a connective tissue stroma which is composed of fat 
cells and a meshwork of blood vessel, branching fibroblasts, macrophages, some myelinated and non-
myelinated nerve fibers and a small amount of reticulin. Stromal cells are comprised of reticular cells, which 
include two cell types of different origin: phagocytic reticulum cells (macrophages that originate from a 
hematopoietic progenitor) and non-phagocytic reticulum cells (closely related to fibroblasts, adventitial cells 
and probably also osteoblasts and chondrocytes). These cells and their products (humoral factors) constitute 
the microenvironment, and there is a close interaction between hematopoietic cells and their 
microenvironment, because each one can modify the other. 
 
1.3.2.2 Multipotent myeloid stem cells 
 
Multipotent myeloid stem cells give rise to all types of myeloid cells: erythrocytes, granulocytes; 
macrophages, monocytes; mast cells; megakaryocytes and all their precursors. It should be mentioned that 
the term 'myeloid' can be used with two different meanings. It is used to indicate all cells derived from the 
common myeloid stem cells and also to indicate only the granulocytic and monocytic lineage as in the 
expression 'myeloid:erythroid ratio'. It is usually evident from the context which sense is intended but it is 
important to avoid ambiguity in using this term. The various myeloid lineages differ both morphologically and  
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in their disposition in the BM. Multipotent myeloid stem cells do not give rise directly to mature cells. For a 
macrophage, for example, the first step will conduct to a cell that is still capable of differentiating into either a 
macrophage or a granulocyte (GM-CFU, see figure 2). In a second step, the cell will be definitively 
committed to become a macrophage (M-CFU), and can no more differentiate into other lineages such as 
granulocyte, erythrocyte or lymphoid cell. But before a mature macrophage is formed, at least three more 
steps are necessary. In fact, this M-CFU will first become a monoblast, then a promonocyte, a monocyte and 
finally a macrophage. These different steps are characterized by the presence of either common cluster of 
differentiation (CD) at the surface of the cell, for example CD33, or of specific CD (like CD15). CD33 
probably functions as cell adhesion molecule and is present from the earlier step of differentiation (CFU-
GEMM) till the stage of monocyte, whereas CD15 mediates phagocytosis and chemotaxis, and is present 
only at the stage of monoblast (see figure 2). 
 
 
1.3.2.3 Multipotent lymphoid stem cells 
 
As for myeloid stem cells, lymphoid cells also have a common precursor called lymphoid stem cell. Moreover 
B and T lymphocytes share a common origin with myeloid cells, all of these lineage being derived from a 
multipotent stem cell. The lymphoid stem cells can differentiate into B lineage (if it stays in the marrow in 
mammalian, or if it migrates to the bursa of Fabricius in bird) or into T lineage (if it migrates to the thymus). 
Once more, it does not directly differentiate in mature cells, but undergoes different stages of maturation. In 
contrast to myeloid cells, that differentiate in the BM and then act in the blood, B and T migrate through three 
organs. B cells differentiate in the BM, circulate in the blood, but their major concentration is found in the 
lymph nodes. T cells migrate from BM to thymus where they differentiate and then circulate in the blood and 
also populate the lymph nodes. 
 
1.3.2.4 Differentiation 
 
Cell differentiation is accomplished via a complex interaction between the different components of the 
marrow (cells and humoral factors). In certain cases, the first step of differentiation consist in migrating to the 
specific organ (i.e. thymus for T cells). This migration, as other steps of differentiation, depends on the 
microenvironment composition. Normally, precursors cells follow a normal pathway of cell cycle (G1/S/G2/M) 
and reproduce themselves (this self-renewing can also be stimulated, i.e. in the presence of IL-7, pre-B cell 
13 
  
increase the self-renewing rate). Only when the environment contains the right factors, cells begin to 
differentiate into specific lineages (i.e. the presence of IL-4 will stimulate pre-B cell to mature into B cell). To 
appreciate the complexity of the differentiation process, we will describe some of the steps that leads to 
mature B cell. The first step in the development of the stem cell into mature IgM+IgD+ B cells is antigen-
independent and occurs primarily in the BM. IL-7 is a potent growth factor for B cell progenitors, but it does 
not appear to act on mature B cells. In vivo, infusion of IL-7 into mice increases the number of lymphoid cells 
in spleen and lymph nodes and the number of marrow pre-B cells.42 In contrast, IL-4 induces proliferation of 
pro-B cells and their differentiation into early pre-B cells and then into mature IgM+ B cells.43 However, 
infusion of anti-IL-4 neutralizing antibodies did not result in an alteration of B cell numbers in lymphoid 
organs, whereas such treatment profoundly inhibits the increase of serum IgE levels following parasite 
infection or anti IgD production.44 
The second step, from mature resting B cell to plasma cells and memory B cells, is antigen-dependent as 
well as T cell dependent and occurs mostly in secondary lymphoid organs. This is a complex process that 
requires antigens and the collaboration between B cells, T cells and antigen presenting cells. This process 
can also be subdivided into two stages: (i) First, B cells specifically bind the thymus-dependent (TD) antigen, 
by means of their surface Ig receptors. The antigen is then internalized, processed and re-expressed in 
association with major histocompatibility complex (MHC) class II determinants and finally presented to the T 
helper (Th) cell. (ii) The second stage permits expansion and differentiation of the antigen specific B cell 
clones and is essentially under the control of T cell-derived soluble factors. 
By this complex mechanism a relatively small cell number can fight a large number of antigens. On the other 
side, by renewing a small number of progenitor cells one can obtain, in short time, a great number of 
specialized cells. In fact, the marrow is composed of lymphoid and myeloid cells at different stage of 
maturation, and when one special population is needed, it will be produced not from the stem cell, but from 
the closest precursor. Only in a second time the precursors will be substituted by maturation of more 
undifferentiated cells or by self-renewal. A control of such a system can be achieved only through a large 
number of soluble factors (interleukines, hormones, neural factors) coupled with cell interaction. 
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Figure 2: Principal step in differentiation of hematopoietic stem cells to mature blood cells and site of 
maturation 
 
 
 
2 Neural regulation of hematopoiesis 
 
The multiplicity of hematopoietic regulators reflects the need for a subtle physiological control of the complex 
cell population at any given situations. This poses several problems in our understanding of hematopoiesis, 
and it poses even more problems from the clinical point of view because of the need to evaluate thousand of 
combinations of the different hematopoietic regulators. Single hematopoietic regulators are already used to 
counteract the BM toxicity of cancer chemotherapy compounds or to enhance hematopoietic regeneration 
after bone marrow transplantation (BMT). However, such procedures remain problematic because of 
negative side effects and high costs.41 An endogenous modulation of hematopoietic regulators presents 
substantial advantages over exogenous administration and circumvents the need for testing thousands of 
regulators combinations. Working on this line, Maestroni et al35,45,46 studied whether melatonin, an 
hormone produced by the pineal gland, was involved in the hematopoietic regeneration in mice after lethal 
irradiation and syngenic BMT. Knowing that melatonin production is inhibited during the light phase of the 
day, mice were kept under permanent lighting (24 h light, L24) or were surgically pinealectomized to 
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investigate whether normal hematopoietic reconstitution was influenced by melatonin. Mice kept under 
permanent lighting showed decreased peripheral blood leukocytes (PBL) and platelets counts, but, 
surprisingly, this inhibition was also present in pinealectomized mice. Moreover, supplementation of 
melatonin in L24 exposed mice did not reverse the negative effect of L24. 
This demonstrated that melatonin was not involved in the effect of permanent lighting. It was then 
hypothesized that the effects observed depend on a neural and not on an hormonal mechanism. The rational 
of such a hypothesis was the following: beside the main optical system, light activates the accessory optical 
tract which includes the suprachiasmatic nucleus and the supracervical ganglia (SCG).47 From the SCG, 
efferent sympathetic fibers directly innervate the pineal gland and the thymus, other nerve fibers send 
projections down to the spinal cord, and consequently might reach the BM via paravertebral and prevertebral 
ganglia.47,48 Because part of this network regulates melatonin synthesis in pineal gland via release of NE, it 
was reasonable to think that also in the BM, inhibition of hematopoietic reconstitution after BMT could be 
mediated by a modulation of NE release from sympathetic terminals in the BM. Maestroni et al.49 
demonstrated that treatment of mice with 6-hydroxydopamine (6-OHDA), a substance that induces a 
profound, although temporary, NE depletion,50 counteract the effect of constant lighting after BMT. On the 
other hand the α1-adrenergic (α1-AR) antagonist prazosin (PRA), but not the β-bloker propanolol (PRO), 
mimicked and extended the effects of 6-OHDA, also inducing a rapid and significant increase of platelets, 
marrow GM-CFU, and nucleated spleen cells. Differential count of white blood cells and histological analysis 
of spleens from PRA-treated mice confirmed that myelopoiesis was greatly enhanced.49 When PRO was 
administered in combination with PRA, however, the increase of platelets disappeared, suggesting that this 
part of the effect was under β-ARs control. Adrenergic agonists and antagonists were effective not only after 
BMT, but also in normal mice. Consistently, NE and/or adrenergic agonists could inhibit growth of GM-CFU 
in vitro. 
 
3 Adrenergic Receptors 
 
Adrenergic receptors belong to the seven-chains-transmembrane spanning family of receptors. These are 
normally coupled to a G protein and they respond to the physiological agonists NE or E (see table 4). 
Adrenoceptors are divided into two types, alpha and beta adrenoceptors. These can be subdivided into many 
subtypes. The alpha type are subdivided in alpha 1 (which is subdivided in alpha 1A, alpha 1B and alpha 1D) 
and alpha 2 (which is subdivided in alpha 2A, alpha 2B and alpha 2C). The beta adrenoceptors have been 
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classified into beta 1, beta 2, beta 3, and beta 4 subgroups. Although these receptors are hystorically related 
to nervous cells for the propagation of the nervous signal from one neuron to another, or to organs (i.e. 
muscle), in the last two decades evidence has been produced that these receptor are expressed by a wide 
number of cell types, and mediate many cell function. In the hematological field, already in 1984 Titinchi et 
al.51 reported the presence of adrenoceptors (α2) on human lymphocytes. In the following years many 
studies reported the presence of different adrenoceptors in different cell types. For example, in 1985 
Hellstrand et al.52 reported that natural killer (NK) activity was increased by E when cells were preincubated 
with E, while the NK activity was inhibited when E was added directly in the lymphocytes/target mixture. In 
1994, Bergquist et al.11 reported the presence of endogenous catecholamines and their metabolites in 
single lymphocytes and in extract of T- and B- cell clones. These authors also reported the existence of an 
uptake mechanism for catecholamines, resulting in a dose-dependent inhibition of lymphocyte proliferation. 
These results suggested a catecholaminergic regulation of lymphocyte function via an autocrine loop. In 
summary, Lymphoid cells produce, release and re-uptake catecholamines, and express different adrenergic 
receptors (AR). The effect of chatecholamines on lymphoid cells may be very different depending on cell 
type, doses of catecholamine and timing of treatement. 
 
Receptor type a1A a1B a1D 
Potency order NE ≥ E E = NE E = NE 
Transduction 
mechanism 
activates Gp/q, ↑ PI turnover, ↑ [Ca2+], activates voltage-gated Ca2+ channels 
Receptor type a2A a2B a2C 
Potency order E ≥ NE E ≥ NE E ≥ NE 
Transduction 
mechanism 
activates G i/o, inhibits adenylyl cyclase, ↓ cAMP, inhibits voltage-gated Ca2+ channels, 
activates Ca2+-dependent K+ channels 
Receptor type β1 β2 β3 β4 
Potency order NE ≥ E E > NE NE > E  
Transduction 
mechanism 
↑ adenylyl 
cyclase (via GS) 
↑ adenylyl cyclase 
(via GS) 
↑ /↓ adenylyl cyclase 
↑ adenylyl cyclase 
↓ adenylyl cyclase 
↑ cAMP levels, ↑ of 
cAMP-dependent protein 
kinase (via GS) 
Table 4: Subdivision of adrenergic receptor, and normal transduction pathway 
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4 Aim of the present study 
 
Maestroni et al., demonstrated that this inhibition is exerted on ARs present on BM cells.53 Moreover, by 
functional and pharmacological studies, they showed the presence of two specific binding sites for 3H-PRA 
which differed in their affinity. Competition studies characterized the high affinity site as an α1b-AR. The 
remaining site was of less clear characterization and the results obtained were compatible with low affinity 
α1-AR. Separation of BM cells by counterflow centrifugal elutriation resulted in separation of the two ARs, 
with the α1b-AR being partially eluted in lymphoid fraction containing no blasts and no assayable GM-
CFU.53 These findings led to the conclusion that hematopoiesis may be modulated via bone-marrow α1-
ARs. It is well documented that BM sensitivity to cancer chemotherapeutic compounds is to a great extent 
related to the cell proliferation rate.54 The purpose of this study was, therefore, to identify the cell types 
bearing the α1-ARs and to investigate the feasibility of an adrenergic modulation of the hematological toxicity 
of anti-cancer chemotherapy compounds or X-rays irradiation. 
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1. INTRODUCTION 
Carboplatin (CBP) is one of a series of platinum coordination complexes which was first reported to have 
antitumor activity in experimental animal tumors in 1969 by Rosenberg.55 
Pt
O
OH3N
H3N
O
O
C6H12N2O4Pt  
Figure 3: Structure of CBP 
The compound acts via hydratation of platin which is then free to bind with O6 or N7 of the DNA guanine. This 
reaction, with the formation of closed-ring chelate, results in interstrand and intrastrand DNA cross-linking 
and DNA-protein cross-linking. It is generally thought that the resulting inhibition of DNA synthesis is 
responsible for the antitumor effect of the compound. The interest of this molecule is that it is active on a 
wide range of tumors, if administered only once. This was important because the model of NE treatment 
needs a treatment as short as possible. Moreover CBP, in contrast with other chemotherapeutic substances, 
is toxic in the BM and in other tissue with high proliferation rate, probably because it acts only on “opened” 
DNA typical of proliferating cells 
The major problem occurring after treatment with CBP is its myeloablative effect. The aim of this study was 
to find out whether NE could interact in any way with CBP. Because NE inhibits cells growth particularly of 
GM-CFU, the hypothesis was, that the inhibition results in not “opened” DNA and consequently in protection 
of the cells. 
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2 MATERIALS AND METHODS 
 
2.1 Mice 
Female 2-3 months old C57BL/6 inbred mice were purchased from Charles River Italia, Calco, Italy. The 
mice were kept under a 12 h light-dark cycle at 21 ± 1°C with free access to food and water. 
 
2.2 Drugs 
L-norepinephrine-HCl (NE), prazosin (PRA) and carboplatin (CBP) were purchased from Sigma Co., St. 
Louis, USA. Agar is purchased from DIFCO Laboratories, Detroit, USA. 
 
2.3 In vivo experiments 
C57BL/6 mice were either treated with one single, lethal intravenous, injection of CBP (200 mg/Kg body 
weight) or exposed to 300-900 cGy (X ray) TBI using a linear accelerator (15 MV energy equivalent). NE was 
injected subcutaneously 1 h and immediately before CBP, as well as 2 h and 4 h after CBP. In the irradiation 
experiments, NE was injected 4 h, 2 h and 30 min before X ray exposure. Control mice were injected with NE 
or Saline (Phosphate buffered saline, PBS) according to the schedule used in CBP experiments. When PRA 
was administered to CBP-treated mice, a single injection of 10 mg/kg body weight either alone or with NE 
was performed. The concentration of PBL (L), platelets (P) and marrow ganulocyte/macrophage colony-
forming unit (GM-CFU) was determined 3 days after treatment using a standard method. Briefly peripheral 
blood was obtained by a little cut of the tail, and leukocytes were simply counted under a microscope with 
türk coloration (to eliminate erythrocytes). Platelets were counted after diluting in Plaxan (Erne AG, Dällikon, 
CH). 
 
2.4 In vitro experiments 
For GM-CFU experiments we used a modification of the method described by Brandley and Metcalf.56 Mice 
were sacrificed by cervical dislocation and BM cells were collected by flushing out the marrow from the 
bones with a sterile syringe filled with α-minimal essential medium (α-MEM). Cells were washed once and 
105 cells were resuspended in 1.5 ml 0.3% semisolid agar in α-MEM containing 20 % horse serum (HS), 
10% of lung conditioned medium (LCM, as source of GM-CSF) and the different substances (NE, CBP, etc.). 
LCM was prepared by mincing the lungs from 2 months old C57BL/6 mice. The supernatant was collected 
after incubation at 37°C in the presence of 5% CO2 in α-MEM, 20% HS for 3 days. Cultures were then 
incubated during 7 days at 37°C, in humidified air and 5% CO2. Colonies containing more that 50 cells were 
evaluated as GM-CFU by phase contrast microscopy. 
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3 RESULTS 
 
3.1 NE protects GM-CFU from the toxic effect of CBP 
GM-CFU is a method used to evaluate the concentration of a population of precursor cells (GM-precursors) 
that is normally present at very low concentration in the BM (less than 1%). We therefore incubated BM cells 
as described in materials and methods in the presence or absence of NE. We found that NE inhibits the GM-
CFU in a dose dependent manner. As it is shown in figure 4, NE has no effect until nM concentrations, then it 
exercises a dose-dependent inhibition, up to over 80% at mM concentration. 
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Figure 4: NE inhibition of GM-CFU of BM cells. NE was dissolved in α-MEM containing 20% HS and added 
at the reported concentrations in the cell suspension before plating. a: p< 0.01. 
 
 
3.2 NE protects mice from lethal dose of CBP and from X-rays exposure 
In a first series of experiments we treated mice with CBP with or without NE at different concentrations. 
Figure 5 shows that NE was highly effective at protecting mice from the toxic effect of CBP at 1, 2 and 3 mg / 
Kg body weight, while the NE effect decreased at 4 mg / Kg body weight (p=0.007) with a bell-shaped dose-
response curve. In all cases the most effective dose of NE was 3 mg / kg body weight, and we used this 
dose for all the other experiments. 
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Figure 5: Survival of mice treated with CBP ± NE. The mice were injected with CBP and treated with NE 
according to the protocole described in materials and methods and then observed daily for survival. 
 
To investigate whether the protective effects exerted by NE depended on a direct hematopoietic protection, 
we treated mice with NE, either before or after X ray irradiation or CBP injection. We measured the blood 
concentration of leukocytes (L), platelets (P) and GM-CFU in the BM. As expected, these parameters were 
increased in NE treated mice when compared with control mice. On the other hand, NE did not affect 
hematopoiesis in normal mice (not treated with CBP nor irradiated). 
 NE PBS 
 L / µl (x 103) P / µl (x 103) GM-CFU / 
femur 
L / µl (x 103) P / µl (x 103) GM-CFU / 
femur 
TBI 300 cGy 1.9 ± 0.11 b 26.5 ± 1.2 b 3634 ± 861b 0.9 ± 0.2 18.1 ± 1.6 1659 ± 611 
TBI 400 cGy 1.3 ± 0.15 b 23.1 ± 0.9 b 4680 ± 979 b 0.7 ± 0.1 17.3 ± 0.6 1749 ± 627 
TBI 500 cGy 1.02 ± 0.2 19 ± 0.35 1029 ± 208 c 1.1 ± 0.3 17.8 ± 1.4 423 ± 249 
CBP 5.8 ± 1.6 a 54.3 ± 21.9 a 3630 ± 1721 a 2.5 ± 0.7 26.1 ± 13 995 ± 535 
CONTROL 10.6 ± 2.1 232 ± 37 7695 ± 1356 9.6 ± 2.6 225 ± 27 8870 ± 1235 
 
Table 5:  Protection of blood (leukocytes; L; and Platelets; P) and bone marrow (GM-CFU) parameters by NE 
(3 mg / kg body weight) in mice treated with CBP (200 mg/ kg body weight) or exposed to TBI. a: 
p< 0.001; b: p< 0.005; c: p< 0.05 
 
In other experiments, lethally irradiated mice (900 cGy) were treated with NE, but in this case NE was not 
able to protect mice. 
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Figure 6: Time curse of the hematopoietic response to NE in mice treated with CBP. The mice were injected 
with CBP and treated with saline or NE (3 mg/kg). The number of GM-CFUs was evaluated after 
treatment at time reported. Day 0 means 1 hour after the last NE injection and 5 hours after CBP 
inoculation. The mean value ± the standard deviation of 10 mice per group is reported. a: p < 0.001 
 
As shown in figure 6, in a time-curse study of hematopoietic response, NE was effective in protecting 
myeloid precursors as early as 5 hours after CBP administration and 1 hour after the final NE injection. 
 
3.3 Prazosin abolished the effects of NE 
To investigate whether NE protection was mediated by α1-adrenergic receptors (α1-ARs) we repeated the 
rescue experiments in vivo (figure 5) by the addition of the α1-adrenergic antagonist PRA. As expected, PRA 
neutralized 80% of the rescue effects in mice injected with CBP and treated with NE. Again, this suggests 
that NE may protect BM via α1-ARs. 
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Figure 7: Effect of PRA on survival of mice treated with CBP and NE. All mice were injected with CBP. 
 
 
3.4 NE protects bone marrow cells in vitro 
The GM-CFU in the presence of CBP results in no colony formation, probably because the method involves 
a 6 day incubation of a small number of cells, and, under these conditions, CBP may kill all hematopoietic 
progenitors. For this reason, in our experiments 3x106 cells/ml were pre-incubated for 7 h with the various 
substances (NE, CBP, etc.). After incubation the cells were washed trice and plated in a standard GM-CFU 
assay. Under these conditions, NE alone did not inhibit GM-CFU colonies (see figure 8). However, NE 
protected GM-precursors from the toxic effects of CBP. Moreover, when PRA was added, the NE-induced 
protection was completely abolished, suggesting that the protection was mediated by α1-ARs. In addition, 
these effects were very specific, with a bell-shaped dose response curve. In fact, low PRA concentrations 
(ca. 10-11 M) abolished 100% of the protective effect of NE. Higher or lower concentrations of PRA 
counteracted only partially the NE effects. 
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Figure 8: α1b-adrenergic receptor-mediated rescue of GM-CFU in CBP-treated BM cells. BM cells were 
incubated at 37°C for 7h with CBP (25 µM), in the presence or absence of NE and with the 
reported concentrations of the α1b-adrenergic receptor antagonist PRA. Control cultures were 
incubated with tissue culture medium (MEDIUM), PRA or NE alone. a: p<0.01 
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4 DISCUSSION 
In this study we showed that NE may protect, either in vivo or in vitro, BM cells from the toxic effects of CBP 
or X-ray TBI. However NE does not protect lethally irradiated mice. The reason for this is unclear and needs 
further studies. We report a dose-response curve of NE in vivo that shows a decreased protection from 3 to 4 
mg / kg body weight. This might be explained by a non-specific toxicity of high doses of NE, or by a real bell-
shaped biological response. In vivo, the differences between mice treated with NE and PBS are reflected on 
blood parameters only three days after treatment. When blood parameters are evaluated just after the 
treatment no significant difference is apparent. However, on the bone marrow GM-CFU concentration the 
effect was already measurable after few hours. This suggests that NE protection was exerted on 
hematopoietic progenitors. This protection is probably mediated via specific α1-ARs because the specific α1-
adrenergic antagonist PRA neutralized the effect. The fact that this is abolished only partially by PRA may be 
explained by the presence of other ARs on hematopoietic cells. This is consistent with the observation of 
Maestroni et al.49,53 that addition of the β-adrenergic antagonist PRO counteracted PRA-induced 
enhancement of platelet formation. This suggested that a β-adrenergic dependent mechanism is involved in 
platelet generation. On the other hand, it has been previously shown that BM cells express two α1-
adrenoceptors, with high and low affinity for 3H-PRA respectively. Since only 1 nM PRA is required for 
neutralizing the NE effect in vitro, probably tehe receptor involved is the high affinity one (Kd = 1 nM). In 
conclusion our results suggest that NE participates actively in the regulation of hematopoiesis via specific 
ARs present on BM cells. 
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III. IDENTIFICATION OF BONE MARROW CELL 
POPULATION BEARING THE HIGH AFFINITY α1-
ADRENERGIC RECEPTOR 
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1. INTRODUCTION 
In the previous chapter we have demonstrated that the NE-induced modulation of hematopoiesis via α1-AR 
may result in rescue mechanism when mice are treated with lethal doses of CBP. Moreover, we showed that 
PRA counteracts at least part of this rescue, both in vivo (when PRA is injected in vivo to counteract the 
rescue effect of NE against CBP) and in vitro (when protection is measured on GM-CFU). The concentration 
of PRA needed to counteract such protection in vitro, suggested that this effect was mediated by the high 
affinity AR. For this reason, we were interested to know which cell type bears the α1b-AR. This is 
fundamental for understanding if the mechanism is mediated via the release of a soluble factor (cytokine) or 
if the AR bearing cells modulate directly BM cell proliferation. 
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2. MATERIALS AND METHODS 
 
2.1 Drugs 
L-norepinephrine (NE), prazosin (PRA), phentolamine-HCl (PHE) were purchased from Sigma (St. Louis, 
MO). 3H-PRA is purchased from NEN Du Pont de Nemours, Regensdorf, Switzerland. 
 
2.2 Antibodies 
Rat anti B220 monoclonal antibody (IgG2a) was purchased from PharMingen, San Diego, USA. Rat anti-
Mac1 monoclonal antibody (IgG2b) and FITC-conjugated mouse anti-rat-IgG2a or-IgG2b monoclonal 
antibody were purchased from Readysystem, AG, Bad Zurzach, Switzerland. FITC-conjugated goat anti-
mouse IgM (µ-chain specific) was purchased from Sigma Immuno-chemicals, St. Louis, MO, USA. Goat anti-
rat IgG antibody coupled to paramagnetic micro-beads was purchased from Miltenyi Biotec GmbH, Berghish 
Gladbach, Germany. 
 
2.3 3H-Prazosin binding 
BM cells were suspended at 2x106 cell/ml in α-MEM with 1% HS in the presence of various concentrations 
(0.05 to 20 nM) of 3H-PRA at room temperature for 1 hour. Non specific binding was assessed by addition of 
100 µM PHE. The assay was terminated by filtration trough Titertek-TM glass fibre filters, and the activity 
was counted by liquid scintillation in Ultima Gold MW and with a β-counter type 1900 of Canberra Packard, 
Meriden, CT, USA. 
 
2.4 Separation of bone marrow cells by adherence 
BM cells obtained as described in the previous chapter, were suspended in α-MEM with 5% HS at 
concentration of 3.5x106 cells/ml and incubated overnight (16-18 h) at 37°C in 5% CO2 in tissue culture flask 
(Costar, Cambridge, MA, USA). After incubation, non-adherent cells (n-ADH) were obtained by harvesting 
the supernatant. Adherent and loosely-adherent cells (ADH) were harvested after addition of PBS with 5 mM 
EDTA for 10 min at room temperature. To optimize cell recovery, culture flasks were washed with PBS three 
time. 
 
2.5 Magnetic cell sorting 
The magnetic cell separator MACS, was purchased by Myltenyi Biotec GmbH, Bergish Gladbach, Germany. 
Adherent BM cells were suspended at 107 cells/0.1 ml and incubated in PBS with 2% HS for 30 min at 4°C 
30 
  
with 30 µl rat-anti mouse Mac1 or B220 monoclonal antibody. After washing, cells were incubated again for 
30min at 4°C with goat anti rat IgG conjugated with paramagnetic micro-beads. The secondary antibody was 
used only in the case of Mac1+ antibodies, while anti-B220 primary antibodies was already coupled to 
magnetic micro-beads. Cells suspended at 107 /0.1 ml were incubated 30 min at 4°C with anti B220 micro-
beads coupled antibody. After 3 washings, cells were loaded on to a steel-wool column where labeled and 
unlabeled cells were magnetically separated. Enrichment was obtained by eluting cells using an A2 column 
with a G24 needle for flow regulation. For depletion, the flow was regulated using a G27 needle. Efficiency of 
separation was evaluated by flow cytometry. 
 
2.6 Long-term cultures of B-cell precursors 
Amplification of B-cell precursors was obtained by a modification of a method previously described.57 Briefly, 
4x106 BM/ml were incubated overnight in α-MEM, 10 µM 2-mercaptoetanol (2-ME) and 10% HS. The culture 
medium was then discarded with n-ADH and replaced with an equal amount of fresh α-MEM containing 10% 
fetal calf serum (FCS) and human recombinant interleukin 7 (IL-7, 500 U/ml) kindly provided by Sterling 
Winthrop Inc., Collegesville, PA, USA. Twice a week, half of the culture medium was replaced with fresh 
medium containing 1000 U IL-7/ml. By 28 days virtually all non-adherent and loosely adherent cells 
appeared to be Mac1-, sIgM-, B220+ lymphocytes. 
 
2.7 Flow cytometry 
Depleted, enriched or cultured cell populations were washed trice and 106 cells/sample were incubated for 
30 min at 4°C with saturating concentrations of anti Mac1, anti B220 or FITC-conjugated goat anti-mouse 
IgM. The fractions which were already B220+ or Mac1+ labeled, were then washed twice and incubated with 
FITC-conjugated mouse anti-rat-IgG. After further washing the cells were analyzed by flow cytometry 
(FACScan, Beckton Dickinson, Mountain View, CA, USA). 105 cells were analyzed per sample. Negative 
controls included unstained cells and cells stained with the secondary antibody only. The percentage of 
positively staining cells was calculated on a channel-by-channel subtraction of the control data (secondary 
antibody alone) from experimental data. 
 
2.8 Incubation with anti-TGF-β 
BM cells were processed as described in point 2.3 of chapter 2 for the “direct” GM-CFU. For an “indirect” 
GM-CFU, 3 x 106 cells / ml were suspended in α-MEM with 5% HS and incubated for 8h in triplicates in the 
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presence of CBP with or without NE and/or anti-mouse transforming growth factor-β (TGF-β) monoclonal 
antibody. After incubation at 37° C in 5% CO2 in 24 wells tissue culture plates (Becton Dickinson, Oxnard, 
CA, U.S.A.), the cells were washed trice and processed for the GM-CFU assay. 
 
2.9 Umbilical cord blood cells 
10 ml of umbilical cord blood were diluted in 25 ml RPMI 1640 (BioConcept, Allschwill, CH) and loaded on 15 
ml Ficoll 1.077. After 30 min centrifugation at 400 x g at 20°C, the cells on the interface between Ficoll and 
RPMI were harvested, washed three times and diluted at 2x106 cells/ml for binding studies. 
 
2.10 Cell line cultures 
NALM-6 was kindly provided by Dr Seckinger, Centre d’immunologie INSERM-CNRS, Marseille, France. 
KM-3 was kindly provided by Prof. Trubiani, Istituto di Citomorfologia Normale e Patologica del CNR, 
Università di Chieti, Italy. 70Z/3 was purchased from ATCC. Cells were maintained at concentration between 
0.1 and 1 x 106 cells / ml in RPMI 1640 with 10% FCS and, for 70Z/3, 5 mM 2-ME. 
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3 Results 
 
3.1 Distribution of α1-adrenergic receptors in adherent vs. non-adherent cells 
In previous works Maestroni and co-workers49,53 demonstrated that the two ARs-bearing cell populations 
could be separated into two distinct CCE cell fractions. Unfortunately, both fractions were heterogeneous in 
their cell composition and it was impossible to determine which cell population expressed α1-ARs. However, 
we found that the fraction which expresses only the low affinity receptor included most of the GM precursors. 
In contrast, in the fraction showing the high affinity receptor, no GM-precursors were found. This suggested 
the existence of two cell populations expressing different α1-ARs. By searching a way to separate these cell 
populations we found a simple adherence procedure (see materials and methods) to be effective. In the 
adherent fraction (ADH) both receptors were still present, while in the non-adherent one (n-ADH) the high 
affinity receptor seems to be absent (Table 6). In the latter fraction (n-ADH) an assessable number of GM-
precursors was present. A GM-CFU assay demonstrated that NE was not active. This was in contrast to 
what happened in unseparated BM cells, were NE shows a significant growth inhibition of such precursors 
(figure 4, chapter 2). This strongly suggested that GM-CFU inhibition occurred via the high affinity receptor 
which seems to be absent in the n-ADH fraction (Figure 11). As shown in Figure 11 high concentrations of 
NE (10-4 M) are necessary to inhibit GM-CFU in n-ADH cells in contrast with unseparated BM cells where 10 
nM NE exerted a significant GM-CFU inhibition (figure 4, chapter 2). 
 
 Kdhigh nM Bmaxhigh 
fM/106 cells 
Adherent 
cells 
1.14 ± 0.64 5.2 ± 2.3 
Non-adherent 
cells 
— — 
 
Table 6: Distribution of α1-AR in adherent vs. non-adherent BM cells. BM cells were collected from C57Bl/6 
mice and incubated as described in materials and methods to separate adherent from n-ADH. The 
cells were then washed and adjusted at concentration of 2x106 cell/ml to perform binding study. 
The values represent the mean of 4 experiments ± SE and have been obtained by a computer-
assisted non-linear regression analysis (Ligand).58 
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Figure 9: Plot of saturation isotherm of 3H-PRA binding in adherent (ADH) and non-adherent (NADH)cells. 
Non linear regression analysis gave two binding sites for the ADH and on for the NADH fraction as 
reported in Table 6. The result are obtained by the mean of tree different experiments. 
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Figure 10: Noradrenergic inhibition of GM-CFU in unseparated vs. non-adherent BM cells. For each 
concentration the mean value from 5 experiments ± SD is shown. a: p< 0.01. 
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NE sensitivity of ADH cells was not tested because, as previously reported,59 GM-CFU precursors are 
practically lacking in this fraction. In this fraction only 10-15 cells over 100’000 cells are GM precursor, and 
this prevents a proper evaluation of possible differences. 
 
3.2 Distribution of α1-adrenergic receptors 
Flow cytometry analysis of ADH cells revealed that two specific antigenic determinants were most 
represented: B220 and Mac1 both at ~ 40%. To separate these two cell populations, Magnetic Cell 
Separation (MACS, described in materials and methods) allows over 75% enrichment or depletion of the 
desired cell population. Binding studies of such populations gave the results reported in Table 7. These 
results suggest that the high affinity receptor is expressed on adherent B220+ Mac1- cells whereas the low 
affinity one is found in this fraction on B220- Mac1+ cells. 
 
Adherent 
cells 
 
% Mac 1+ 
 
% B220 + 
 
Kdhigh nM 
Bmaxhigh 
fM/106 cells 
 
Kdlow nM 
Bmaxlow 
fM/106 cells 
Mac1 
depleted 
6 ± 4 63 ± 6.9 2 ± 1 14 ± 6.3 — — 
B220 
depleted 
67.9 ± 7.8 10.7 ± 10.6 — — 46 ± 19 200 ± 80 
Mac1 
enriched 
81 ± 4.3 12 ± 5 — — 54 ± 12 189 ± 36 
B220 
enriched 
13.4 ± 1.3 74.4 ± 14.1 1.5 ± 0.9 56.4 ± 5.4 — — 
Table 7: Characterization of the α1-ARs positive adherent BM cells. The mean values of 5 experiments are 
shown. Variation are SD of percentage and SE of Kd and Bmax. The number of cells per tube in 
the 3H-PRA saturation studies was of 250x103 in the enriched populations and 106 in the depleted 
ones. The Kd and Bmax values were obtained by analyzing together the isotherm saturation curves 
by Ligand.58 
 
3.3 High affinity α1-adrenergic receptor on pre-B cells 
Cells of the B lineage (bearing the B220 antigen) are heterogeneously represented in the BM (pre-B cells, B 
mature cells, plasma cells, etc.). Therefore, we aimed at identifying the B lymphocyte sub-population cells 
which bears the high affinity receptor. 
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Figure 11: Plot of saturation isotherm of 3H-PRA binding in intact spleen cells. The results are obtained from 
two different experiments. Non linear regression analysis gave the scatchard plot reported (inset), 
which describes a single binding site with Kd 50.8 ± 34.2 nM, and B max 177 ± 109 fmol/2x106 
cells. 
 
To answer this question we initially tested whether mononucleated spleen cells, which consist only of mature 
B cells, express the high affinity AR. However, as it appears in Figure 11, mononucleated spleen cells 
contain only the low affinity receptor. This suggests that the high affinity adrenoceptor is expressed on more 
primitive cells. By means of the MACS system it was impossible to obtain a large number of purified primitive 
B cells. Therefore we tried to grow pre-B cells by setting up long term BM cultures by adapting a method 
previously described (see material and methods).57 3H-PRA isotherm saturation studies performed on cells 
obtained after 28 days of culture gave the results reported in Table 8 which demonstrate that Mac1-, sIgM-, 
B220+ B precursors (pre-B cells) indeed express the high affinity α1-adrenergic receptor. 
 
%Mac1+ %B220+ %sIgM+ Kd nM Bmax fmol/106 cells 
0 97 ± 1.5 0 0.83 ± 0.76 12.5 ± 9.6 
Table 8: The mean values ± SD of 3 experiments are shown. The Kd and Bmax values were obtained by 
analyzing the isotherm saturation curves by Ligand.58 
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Figure 12: Plot of saturation isotherm of 3H-PRA binding in non-adherent cells from lymphoid LTBMC. The 
results are obtained from two different experiments. Non linear regression analysis gave the 
scatchard plot reported (inset), which describes one single binding site as reported in Table 8. 
 
 
3.4   Effect of anti-mouse TGF-β monoclonal antibody on the hematopoietic rescue induced by NE 
 
Cells of the B lineage can produce inhibitory cytokines such as tumor necrosis factor-α (TNF-α) and TGF-β.60 
Both cytokines have been reported to rescue hematopoiesis from myeloablative treatments.61,62 TGF-β has 
been also proposed to be a physiological regulator of B cell growth and differentiation.63 We, therefore, 
investigated whether anti-TNF-α or anti-TGF-β antibodies could neutralize the inhibitory effects exerted by 
NE on GM-CFU and, eventually, the NE-induced hematopoietic rescue. As shown in figures 11 and 12, anti-
mouse TGF-β but not anti-TNF-α antibodies were indeed able to counteract the effect of NE both in GM-CFU 
cultures (Figure 13) or in the rescue experiments (Figure 14). These results suggest that activation of the 
high affinity α1-AR present in B cell precursors may induce the production or activation of TGF-β.  
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Figure 13: Noradrenergic inhibition of GM-CFU in unseparated BM cells in presence or in absence of anti-
TGF β monoclonal antibody. Value are the mean of 3 experiments ± SD. a: p < 0.01, NE vs 
Control, NE+a-TNF vs control and vs a-TNF alone. 
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Figure 14: Rescue of GM-CFU in BM cells incubated with CBP via α1b-AR. BM cells were incubated at 37°C 
for 7h with CBP (25 µM) in the presence or absence of NE and anti-TGF-β or anti-TNFα 
monoclonal antibody. a: p < 0.01, CBP+NE vs CBP alone, and for CBP+NE+a-TNF vs CBP and 
vs a-TNF. 
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3.5 High affinity receptor on pre-B cell lines 
Tacking advantage of the results obtained with the long-term cultured normal pre-B cells, we also 
investigated the 3H-PRA isotherm saturation binding on murine and human pre-B cell lines. Two human cell 
lines and one murine cell line have been used. These three cell lines express the high affinity adrenoceptor, 
as shown in Table 9. This confirms the presence of the high affinity α1-adrenergic receptor on pre-B cells, 
both of murine and human origin. 
 
CELL LINE NALM-6 
human 
KM3 
human 
70Z/3 
murine 
Kd nM 0.36 ± 0.05 2.25 ± 0.87 0.98 ± 0.49 
B max fmol /106 cells 1.13 ± 0.08 0.66 ± 0.19 4.08 ± 1.87 
Table 9: 3H-PRA isotherm saturation binding performed on cell lines and analyzed with Ligand. 
 
 
3.6 Adrenergic receptor on umbilical cord blood cells 
Because we found the high affinity α1-AR to be present on human pre-B cell lines, we thought that, in 
analogy with mice, also normal human pre-B cells should express this receptor. As it is rather difficult to 
obtain human BM cells we used umbilical cord blood cells which contain enough hematopoietic progenitors. 
3H-PRA binding Kd Bmax 
high affinity 0.1 ± 0.25 nM 0.61 ± 0.75 fmol / 106 cell 
low affinity 21.7 ± 10.54 nM 8.2 ± 2.62 fmol / 106 cell 
 
Table 10: 3H-PRA isotherm saturation bindings performed on cells harvested from umbilical cord blood, and 
analyzed with Ligand. The results are the value obtained with the cells of one donor. 
 
The results of the binding studies reported in Table 10 also indicate the presence of two different AR in 
umbilical cord blood cells. Moreover the Kd of the high affinity receptor is consistent with our previous results 
obtained on murine BM cells and on pre-B cell lines. 
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4. DISCUSSION 
 
We demonstrated that the high affinity α1-AR is expressed on pre-B cells (B220+Mac1-sIgM-) whereas the 
low affinity receptor seems to be present on ADH and n-ADH Mac1+B220- cells. We did not characterize 
better the low affinity AR because all our experiments suggested that the effects of NE were mediated by the 
high affinity receptor. In fact, we have demonstrated previously that the inhibition of the GM-CFU by NE can 
be completely abolished by addition of 10-100 pM PRA. This is consistent with the Kd measured on BM cells 
for the high affinity receptor (0.98 nM), and suggests that the inhibitory effect was mediated by the high 
affinity α1-adrenergic receptor. In addition, when mice treated with CBP and NE were also treated with PRA 
(10 mg /kg body weight ) part of the protection exerted by NE was neutralized. Similarly, when 1 nM PRA 
was added in BM cells cultures incubated for a short period (7h) with CBP ± NE the effects of NE, i.e. 
protection of GM-precursors against CBP, were neutralized. These observations are consistent with NE 
being effective on the high affinity α1-adrenergic receptor. The next obvious question was, then, the 
identification of the cell type bearing the high affinity receptor. By separating BM cells by adherence we 
confirmed that the GM-CFU inhibition exerted by NE on GM-CFU was performed via the high affinity 
adrenoceptor. Indeed in n-ADH cells, where this receptor was not expressed, NE was effective only at higher 
concentration (0.1 mM). Taking advantage of such distribution we concentrated our efforts on ADH cells and 
we found that two phenotypic markers were most represented in this fraction, namely Mac1+ and B220+. To 
separate these two cell populations, we used the MACS system because it uses small beads (∼ 30 nm) that 
do not interfere with cytofluorimetric measurement and binding studies. By this system the efficiency of 
enrichment or depletion was relatively poor but could be improved by a second elution in the column. Our 
problem was to obtain pure cells in sufficient amount to perform binding studies. For this reason we also 
cultivated cells in long term cultures. The results obtained were very clear: pure pre-B cells (B220+Mac1-
sIgM-) bear the high affinity α1-AR. The same receptor (same affinity for PRA) is also present in human cells, 
in umbilical cord blood cells, and in pre-B cell lines. This indicates that the expression of α1-AR on pre-B 
cells is a common feature and suggests the possibility for a general physiological role of this receptor. The 
mechanism of the inhibition of GM-CFU by NE is still unclear and needs further investigation. For this 
purpose we tested the possible production of a soluble factor but the results were negative. In these 
preliminary experiments, we analyzed the supernatant from normal cells stimulated with NE. The 
supernatant was then dialyzed with a membrane with a cut-off of 4000 Da (to get rid of NE), but it turned out 
not to contain any inhibitory activity. Of course, the hypothetical soluble factor could be smaller than 4000 
Da. Trying to clarify this point we have tested different antibodies against known cytokines and found that 
anti- TGF-β monoclonal antibody was capable to abolish the inhibition of NE. This suggests that a soluble 
factor is indeed synthesized and/or released by the pre-B cells after NE stimulation. Another possible 
mechanism not involving soluble factors is a cell-to-cell interaction between GM-CFU and pre-B cells. 
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IV. NOREPINEPHRINE IN BONE MARROW CELLS 
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1. INTRODUCTION 
We described above the presence and certain biological effects mediated by adrenoceptors in BM cells. 
These findings imply that hematopoiesis may be physiologically regulated by catecholamines. This is also 
suggested by the fact that BM is innervated by both afferent and efferent sympathetic fibers.47 Moreover, it 
has been reported that some blood cells are influenced by catecholamines,11,64 and that lymphoid cells 
may also produce catecholamines.12 In this chapter we demonstrate that murine BM contains substantial 
amount of catecholamines which are not only of neuronal origin but also seems to be produced by BM cells. 
In particular NE and dopamine (DA) showed a circadian rhythmicity with peak values during the night. Finally 
we investigated the possibility of an association of this rhythm with the proportion of cells in the various 
phases of the cell cycle. 
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2 MATERIALS AND METHODS 
 
2.1 Mice  
Female, 2-4 months old C57BL/6 mice were purchased from Charles River, Como, Italy and kept at 21 ± 
1°C, with free access to food and water under a 12 h light:dark photoperiod for at least 15 days before the 
experiments. Light intensity at the level of the cage floor was 800 lux. 
 
2.2 Reagents 
(-)-norepinephrine bitartrate (NE), (+)-epinephrine bitartrate (E), dopamine hydrochloride (DA), 6-
hydroxydopamine (6-OHDA), 3,4 dihydroxybenzylamine hydrochloride, sodium pyrosulfite, TRIZMA base, 
vanillylmandelic acid (VMA), 3,4-dihydroxyphenylglycol (DHPG), 3,4-dihydroxyphenylacetic acid (DOPAC), 
Homovanillic acid (HVA) were purchased from Sigma ST. Louis, MO, USA. All other chromatography 
reagents and solvents were purchased from Merck, Darmstadt, Germany. 
 
2.3 Chemical sympathectomy 
The mice were injected intraperitoneally with 100 mg/kg body weight of 6-OHDA 2 days before sacrifice. In 
adult mice, 6-OHDA produces a profound, although temporary, depletion of peripheral NE, inducing a rapid 
degeneration of sympathetic neurones.50 
 
2.4 Bone marrow collection 
The mice were sacrificed by cervical dislocation. During the dark phase of the photoperiod this operation was 
performed under a dim red light. The marrow was flushed out from the long bones either with culture medium 
(α-MEM with 10% HS) for cell cycle analysis or with 2 ml of HClO4 0.4 N containing 0.84 mg/ml disodium 
EDTA, 25 µl of a 4% sodium pyrosulfite solution, for measurement of the catecholamines. For this purpose 
the samples were then centrifuged (14'000 x g, 4°C, 10 min), the supernatant was frozen and stored at -80°C 
until assayed 
 
2.5 Bone marrow cultures 
BM cells (3x106 cells/ml ) were incubated at 37°C in α-MEM, 10% HS. In certain experiments the cells were 
harvested after 24 h incubation (short term cultures). In others, half culture medium was replaced with fresh 
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medium once a week and the culture was continued for 3 weeks (long term cultures). At the end of the 
cultures, cells were harvested, centrifuged and the pellet processed for catecholamine determination. 
 
2.6 Cell line cultures 
The human pro-B and pre-B  cell lines MO2058, NALM-6 and the murine pre-B cell line 70Z3  which express 
α1-adrenoceptors were cultured in RPMI 1640 medium  supplemented with 10% heat-inactivated FCS, 200 
mM Glutamine, 50 µM 2-ME, 100 U/ml penicillin / 50 µg/ml streptomycin at 37°C in a moist atmosphere of 
5% CO2. 
 
2.7 Catecholamine assay 
BM catecholamines were assayed by high performance liquid chromatography (HPLC) with electrochemical 
detection in supernatants which were aluminia extracted as previously described.65 An analytical Beckman 
C18 ultrasphere-XL ODS 3 µm (70 x 4.6 mm) equipped with XL ODS 3 µm (5 x 4.6 mm) guard cartridge was 
used. The mobile phase was composed of ultrapure water : acetonitrile (82 : 18 v/v), 20 mM K2HPO4, 0.69 
mM EDTA, 0.27 mM SDS. The pH was adjusted to 3.0 with H3PO4 and the solution was filtered (Millipore, 
0.22 µm). Flow rate was set to 0.9 ml/min. An ESA Coluchem II electrochemical detector with 5011 analytical 
cell was used for detection of catecholamines. The first cell potential was set to + 300 mV and the second 
one to - 300 mV. Chromatograms were processed with a computerized integrator. 
 
2.8 Cell cycle analysis 
Mice were injected i.p. with 5'- bromo -2'-deoxyuridine (50 mg / kg body weight, BrdU, Sigma Co., St. Louis, 
U.S.A.) 1 hour prior to sacrifice. BM cells were collected from the femurs, washed in PBS, 1% HS and 
resuspended in 100 µl of PBS at 4° C. The cell suspension was added in drops into ethanol at - 20°C under 
continuous stirring and then incubated on ice for 30 min. The cells were then centrifuged, the supernatant 
removed and the cells resuspended again. After addition of 1 ml HCl 2.5 N in 0.5 % Triton X-100 the cells 
were incubated for 20 min at room temperature. Cells were centrifuged, the pellet was resuspended in 1 ml 
Na2B4O7 0.1 M, pH 8.5, and centrifuged again, resuspended, counted and aliquoted at a concentration of 
10
6 cells / 50 µl in Tween 20, 1 % HS. 20 µl of anti-BrdU-FITC antibody (Beckton Dickinson, Basel, 
Switzerland) were added and the cells were incubated for 30 min at room temperature. Finally the cells were 
resuspended after centrifugation in 1 ml of PBS containing 5 mg / ml of propidium iodide ( Sigma, Co., St. 
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Louis, U.S.A.) and analyzed by cytofluorimetry (FACscan, Beckton Dickinson). The analysis was performed 
by Lysis 2 on 105 cells per gated region. An example of the linear fluorescence intensity plots obtained is 
shown in Figure 15. 
 
2.9 Evaluation of catecholamine concentration and statistical analysis 
The amount of catecholamines in each sample was calculated using peak area ratio relative to 3,4 
dihydroxybenzylamine hydrobromide, the internal standard, to correct for incomplete extraction. The 
concentration of catecholamines was expressed per g of tissue. The statistical tests used were the two-tailed 
Student's t-test for unpaired data, ANOVA and linear regression analysis after log transformation of the data 
in order to homogenize the variance. A cosinor analysis to assess the existence of circadian rhythmicity was 
performed by a computer assisted plot of a least squares fit of a cosine function to the data (Chronolab 3.0) 
 
 
2.10 Cell line cultures 
NALM-6 was kindly provided by Dr Seckinger, Centre d’immunologie INSERM-CNRS, Marseille, France. 
KM-3 was kindly provided by Prof. Trubiani, Istituto di Citomorfologia Normale e Patologica del CNR, 
Università di Chieti, Italy. MO2058 was kindly rpovided by Dr. Gianni Soldati, Ospedale Regionale “La 
Carità”, Locarno, Switzerland. 70Z/3 was purchased from ATCC. Cells were maintained at concentration 
between 0.1 and 1 x 106 cells / ml in RPMI 1640 with 10% FCS and, for 70Z/3, 5 mM 2-ME. 
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3 RESULTS 
 
 
Figure 15: Two color cell cyle analysis using anti-BrdU and propidium iodide. Laser excitation  at 488 nm and 
standard FITC/PI emission filters were used  on FACScan  flow cytometer. (Becton Dickinson). 
 
3.1 Bone marrow catecholamines 
We found that catecholamines are present in substantial amount in the BM. Figure 16 shows the 
concentration of NE (panel A), DA (panel B) and E (panel C) which are present at various times of the day in 
the BM from both normal and chemically sympathectomized mice. It seems evident that NE and E are most 
represented while DA is present at lower concentration. Unlike E, the mean concentration of NE and DA 
seems to be higher in the marrow sampled during the dark phase than during the light phase of the 
photoperiod. To get an index of catecholamine input in the BM over a given time, the data were also 
expressed as area under the curve (AUC). Table 10 reports the AUC relative figures which show that the 
difference in NE and DA mean AUC between the dark and the light phase of the photoperiod is significant. 
Chemical sympathectomy reduced the marrow concentration of NE and DA during the dark phase to levels 
which were similar to those found in the light phase (Table 11). The difference in NE and DA concentration 
between the dark and light phase of the photoperiod suggested the existence of a daily rhythmicity. Cosinor 
analysis of the data revealed the presence of a significant daily rhythmicity of NE and DA in both normal and 
sympathectomized mice (p <0.005 for NE and p < 0.05 for DA, Figure 17 A, B). The daily rhythm of NE was 
apparently reversed by chemical sympathectomy (Figure 17A) while that of DA was shifted with the 
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acrophase occurring at the transition between the light and dark phase (Figure 17B). E did not show any 
significant daily rhythm (data not shown). 
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Figure 16: Measurement of NE (A), DA (B) and E (C) concentration in the BM of normal (open symbols) and 
6-OHDA-treated (closed symbols) mice exposed to a 12h dark:light photoperiod. Each point is the 
mean of at least 9 animals. Vertical bars indicate the standard error.  The black segment of the X 
axis indicates the dark period. 
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Figure 17: Cosinor analysis of NE (A) and DA (B) circadian periodicity in the BM of normal (open symbols) 
and 6-OHDA-treated (closed symbols) mice exposed to a 12 h dark: light photoperiod. The black 
segment of the X axis represents the dark period. Data points are the same as those reported in 
Fig 14. NE (normal mice): rhythm-adjusted-mean (MESOR) = 1823.3 ± 104.3 pg/g  of tissue; 
amplitude (A)=609.0 ± 144.8 pg/g of tissue; acrophase (Φ) = 4h 51 min.  NE (6-OHDA-treated 
mice): MESOR =1413.1 ± 39.0 pg/g of tissue; A= 426.1 ± 61.2 pg/g of tissue; Φ = 18h 16 min. DA 
(normal mice): MESOR =172.8 ± 23.5 pg/g of tissue; A = 11.0 ±  33.4 pg/g of tissue; Φ =5h 53 
min. DA(6-OHDA-treated mice): MESOR = 236.5 ± 15.2 pg/g of tissue; A:106.6 ± 20.4 pg/g of 
tissue; Φ = 0h 46 min. 
 
 Normal 
(pgxg-1xh-1) 
light vs 
dark 
6-OHDA 
(pgxg-1xh-1) 
light vs 
dark 
normal vs 
6-OHDA 
NE light 17409 ± 3082 (n=9)  20223 ± 4641 (n=9)  ns 
NE dark 26507 ± 2418 (n=11) p=0.02 13916 ± 3252 (n=9) ns P=0.005 
      
DA light 1326 ±355(n=9)  2770 ±518 (n=9)   P=0.01 
DA dark 3902 ± 259 (n=9) p<0.001 2312 ± 1210 (n=9) ns ns 
      
E light 5176 ± 3332 (n=9)  8563 ± 2718 (n=9)  ns 
E dark 9623 ± 1572 (n=9) ns 7243 ± 2176 (n=9) ns ns 
 
Table 11. Comparison of AUC relative to BM NE, E and DA in the light and dark phase of the photoperiod. 
The AUC obtained by plotting the concentration of catecholamines against time was calculated 
using the trapezoidal rule and taken as an index of catecholamine input into the BM over a given 
time interval. The values represent the mean pg per g of tissue per hour. n figures stand for 
number of mice per each time point considered. 
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3.2 Catecholamine metabolites 
To investigate whether changes in catecholamine concentrations reflected a change in their turnover, we 
measured the BM concentrations of NE and DA metabolites at two time points during the dark and the light 
phase. The results obtained which are shown in Figure 18A (NE metabolites) and 16B (DA metabolites) 
show that changes of catecholamine concentrations correspond to changes of their metabolites. This 
suggests that the daily rhythm in the BM catecholamine concentration reflects a rhythmic catecholamine 
release and function. 
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Figure 18: NE (A) and DA (B) metabolite concentration in BM sampled during the dark and light phase of the 
photoperiod. Six mice per group were killed at 4 and 8 hour of the dark and light period. The 
values represent the mean of individual values ± standard error of the mean. NE metabolites: NM 
= normetanephrine; VMA = vanillylmandelic acid; DHPG = 3,4-dihydroxyphenylglycol. DA 
metabolites: DOPAC = 3,4-dihydroxyphenylacetic acid; HVA = homovanilic acid. a: p<0.01; b: 
p<0.05 
 
 
 
3.3 Association with bone marrow cell cycle. 
BM functions show a circadian periodicity both in human and mice.66-68 Furthermore, our previous findings 
showed that NE is able to affect hematopoietic functions directly.49,53 Therefore we wondered whether the 
marrow concentration of NE and DA could be associated with any particular change in the proportion of cells 
in the various phases of the cell cycle. The BM from groups of normal and 6-OHDA pretreated mice was 
taken at various times either in dark or light phase of the photoperiod. At each time, the mice were 
randomized in two subgroups as donors of BM cells to be evaluated for catecholamine content and cell cycle 
analysis, respectively. Regression analysis of data show that NE was associated positively (r = 0.39, p = 0.01) 
with the percentage of cells in the G2/M phase (Figure 19 A) and with the percentage of cells in the S phase 
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(r= 0.37, p= 0.02) of the cell cycle (Figure 19 B). When the percentage was substituted for the number of 
cells per femur, the positive association between NE and number of cells in S or G2/M phase remained 
significant (data not shown). No other significant association was found. 
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Figure 19: Positive relationship between NE and the percent of BM cells in G2/M (A) and S (B) phases of the 
cell cycle. At least 6 normal mice per group were sacrificed at 3, 5, 7 and 9 hours of the dark and 
light period. The BM sampled from individual mice from two subgroups of 3 mice then served for 
cell cycle and catecholamine analysis, respectively. At 5, 7 and 9 hours of the dark and the light 
period, 6-OHDA-pretreated mice were also sacrificed and the relative values included in the 
regression analysis. 
 
 
 
3.4 Catecholamines in bone marrow cultures and lymphoid cell lines 
Catecholamines were present either in short term or in long term BM cultures (Table 12). The amount of 
catecholamines contained in the culture medium was undetectable. This suggests that endogenous 
catecholamines in the BM are produced in part by BM cells.  
Our previous studies demonstrated that α1-adrenoceptors are expressed on normal pre-B lymphocytes and 
on both human and murine pro- and pre-B cell lines.69 In the attempt to get a preliminary indication of the 
BM cell type which may produce catecholamines we measured the catecholamine content in MO2058, 
NALM-6 and 70Z3 cell lines and found that these cell lines seem indeed to produce catecholamines (Table 
11).  
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 NE (pg/g) DA (pg/g) E (pg/g) 
STBMC 342 ± 184 677 ± 288 uq 
LTBMC 96 ± 36 113 ± 7 91 ± 47 
Medium uq uq uq 
70Z/3 (m) 153 ± 67 10’380 ± 2937 4018 ± 3829 
MO2058 (h) 1034 ± 541 11’000 ± 4804 4952 ± 1765 
NALM-6 (h) 436 ± 67 8000 ± 4283 5805 ± 1292 
Cell medium uq uq uq 
 
Table 12: The values represent the mean ± SD in pg x g of pelleted cells from 3 experiments. STBMC: short-
term BM cultures; LTBMC: long-term BM cultures; BM Medium: BM culture medium constituted by 
α−MEM, 10% HS; Cell Medium: cell lines culture medium constituted by RPMI 1640 medium 10% 
heat-inactivated FCS, 200 mM Glutamine, 50 µM mercaptoethanol, 100 U/ml 
penicillin/streptomycin. The catecholamine concentration in culture media are relative to freshly 
prepared media. Cell cultures were harvested in the esponential growth phase. uq: unquantifiable; 
m: murine; h: human. 
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4 DISCUSSION 
 
In this study we show that BM contains NE, DA and E. To our knowledge this is the first study showing the 
presence of substantial amounts of catecholamines in the BM. Previous studies were focused mainly on 
peripheral lymphoid organs in rats in which catecholamine concentration was found to be 10-100 fold higher 
than those here reported in murine BM.70-72 The concentration of marrow NE and DA shows a significant 
circadian periodicity with peak values during the night. Chemical sympathectomy seems to reverse the 
circadian rhythm of NE and to advance the acrophase of DA from the middle of the dark phase to the 
transition zone between light and dark phases. However, when the difference in NE and DA between night 
and day was analyzed taking in consideration the intra-group variability, the effect of chemical 
sympathectomy appeared to be just that of abolishing the difference. This might mean that the circadian 
rhythm of NE and DA is due to a circadian periodicity in the activity of the BM sympathetic innervation which 
might well reflect the general sympathetic periodicity in a nocturnal species such as Mus Musculus. On the 
contrary, E did not show any rhythmicity and sensitivity to 6-OHDA , a finding consonant with a non neural 
origin. In our previous work we got evidence that NE exerts an inhibitory effect on hematopoiesis.49,69,73,74 
However, the positive association found is rather surprising as all our previous results indicate that NE exert 
inhibitory action on hematopoiesis. Clearly further studies are needed to clarify this point. The fact that BM 
cells seem to be able to produce catecholamines is also indicative for a physiological role of these 
substances in hematopoiesis. The cell type which may produce catecholamines are unknown. It has been 
recently reported that catecholamines and their metabolites are present in single lymphocytes and extracts of 
T-and B-cell clones and down-regulate lymphocyte function via an autocrine loop.11 Therefore, BM 
catecholamines might derive, in part, from BM lymphocytes or from their precursors. Both for lymphocyte 
function and hematopoiesis the role of catecholamines seems to be inhibitory.11,49,69 In the case of 
hematopoiesis, this inhibition might be exploited in modulating the BM sensitivity to myelotoxic anti-cancer 
drugs.73 
These and our results emphasize the importance of the functional role of catecholamines in hematopoiesis.  
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VI CONCLUSION AND PERSPECTIVES 
 
This work constitutes the continuation of investigations performed previously in our laboratory.49,53 Those 
observations showed the functional presence of ARs in hematopoietic cells. One of the most relevant finding 
of our work was that administration of NE in mice treated with chemotherapeutic substances, could 
neutralize the hematopoietic toxicity of the treatment. We also found that hematopoietic cells express two 
adrenoceptors. It was already reported that mature blood cells express AR, and that these receptors play a 
role in the mobilization of blood cells. In fact, in 1995 Madden et al.72 reported that in vitro, adrenergic 
agonists modulate all aspects of an immune response (initiative, proliferative, and effector phases), altering 
functions as cytokine production, lymphocyte proliferation, and antibody secretion. In vivo, chemical 
sympathectomy suppresses cell-mediated (T helper-1) responses, and may enhance antibody (T helper-2) 
responses. Noradrenergic innervation of spleen and lymph nodes diminish progressively during aging, a time 
when cell-mediated immune function also is suppressed. In animal models of autoimmune disease, 
sympathetic innervation is reduced prior to onset of disease symptoms, and chemical sympathectomy can 
exacerbate disease severity. These findings illustrate the importance of the sympathetic nervous system in 
modulating immune function at the level of mature cells. Nevertheless , to our knowledge, this is the first time 
that such a receptor is reported to be expressed in BM cells precursors. One of these receptors was found to 
be a low affinity α-adrenoceptor. It was not better characterized because our data suggested that it is not 
involved in the hematopoietic effect exerted by NE. The other receptor was characterized as an α1b-
adrenoceptor. At the beginning we had some problems because the receptor was apparently expressed by a 
rare cell population (<1% of the hematopoietic cells). A two steps cell separation resulted in a splitting of the 
adrenoceptors in two cell populations. In one fraction only the low affinity receptor was present, in contrast 
with the other fraction which contained both adrenoceptors. The fact that only the low affinity receptor was 
present in one fraction, allowed us to demonstrate that the absence of the high affinity receptor coincided 
with the absence of the protective effect of NE. By this method we indirectly demonstrated, that the receptor 
responsible for the protection of BM cells was the high affinity one. In addition we showed that the receptor 
was expressed on lymphoid cells, in particular on pre-B cells. The fact that an adrenoceptor expressed on a 
rare cell population like pre-B cells, could protect the entire animal against substances like CBP, is 
remarkable. We tried, therefore, to understand the mechanism through which this protection was exerted. To 
study the mechanism we needed large numbers of cells. For this reason, we decided to use cell lines. Cell 
lines have, in fact, the advantage that they can be easily cultured and in large amounts. On the other side, 
they are immortalized, i.e. have a deranged cell cycle control. This should be kept in mind, especially in our 
experiments in which, apparently  we activated a cell mechanism responsible for the cell growth checking. 
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We showed that NE acts on hematopoietic cells inhibiting their growth, and in some circumstances may 
induce apoptosis. We demonstrated that NE inhibits the growth of hematopoietic precursors. This seems true 
in the cells that express the high affinity adrenoceptor (pre-B), and also in other hematopoietic progenitors 
(GM-CFU). Our study leads to the conclusion that this growth inhibition is responsible for the protection of 
the cells from the toxic effect of CBP. In fact it is known that when cells are resting, their DNA is packed 
(chromatin). In this situation, alchylating substances like CBP, cannot gain access to DNA. We tried to 
demonstrate this mechanism using cell lines, but we encountered many difficulties. The major problem was 
that NE exerted the inhibitory effect on cell line growth only at high concentration (10-4 M). In addition, at this 
elevated concentration NE not only inhibited cell growth but induced cell death. We wondered whether cell 
death was due to apoptosis or to necrosis. We got only a preliminary evidence that NE effect was due to 
apoptosis. We measured Ca2+ release, p53 expression, and lysophosphatidylserine (LPS) on the cell 
membrane (data not show), but we found that only a small amount of cells (~ 20%), was apoptotic. With 
regard to the mechanism of action, autooxidation of catecholamines is considered unlikely because the 
addition of antioxidants (MEL, Vit C, Vit E) could not influence the effect of NE. The fact, that also PRA could 
not counteract the effect of NE further complicated the interpretation of our results. As the effect of 10-4 M NE 
on cell lines was very similar to that obtained with 10-6 M on normal cells, it can be hypothesized that the 
mechanism of action is similar. We demonstrated by pharmacological methods that the receptor in cell lines, 
shows the same affinity for PRA as in normal cells. The work performed is certainly not exhaustive, but it 
elucidates some important points and holds the potential for possible clinical application. If we suppose that 
the effect observed in mice will be similar in humans, we might find a schedule for NE and/or other 
adrenergic agonists treatment. This will allow the use of more effective doses of chemotherapeutic 
substances. Today, a serious problem in chemotherapeutic treatments is their secondary toxicity 
(myeloablatives effects that induces immunodeficiency states). The use of limited doses of drugs to avoid 
toxicity implies low efficiency of anti-cancer treatments. The possibility given by a BM protection with NE 
would allow to increase the dose of the chemotherapeutic compounds without (or at least reducing) the 
secondary adverse effects. Another interesting and new aspect emerging from this work, is the evidence that 
catecholamines may be produced in BM cells. If one can be surprised that cells of the hematopoietic system 
express catecholamine receptors, it seems even more astonishing that BM cells are capable to produce 
catecholamines. However, if these substances have to act as cytokines, it seems reasonable that 
hematopoietic cells can produce them. We investigated not only the presence of catecholamines in these 
cells, but also the presence of their metabolites, and as expected, we found them. In contrast, we were 
surprised to find a positive correlation between the amount of NE in the BM and the percentage of cells that 
were in the G2/M and S phases of the cell cycle. This might depend on a synchronization between NE 
54 
  
rhythmicity and the circadian rhythm of hematopoiesis, or be related by a delayed cause-effect 
mechanism.75 
In conclusion all the results previously obtained and the fact that hematopoietic cells are able to produce 
catecholamines suggest that these substances have a physiological role in hematopoiesis. The cells that 
produce catecholamines seem to belong to the lymphoid lineage: high concentrations of NE were measured 
in lymphoid cell lines and in short term cultures, while lower amounts were found in Dexter type long term 
cultures (myeloid lineage). This is consistent with reports about the presence of NE and its metabolites in 
single lymphocytes and in T and B cell extract, and with the fact that catecholamines and their metabolites 
regulate in a negative fashion lymphocytes function via an autocrine loop.76,77 These results underline the 
importance of the functional role of catecholamines on the hematopoietic system. It is clear that other studies 
are needed to understand the mechanism of these phenomena. On the other hand, data not reported 
showed that NE cannot rescue BM cells against etoposide (ETO). To understand this fact one should 
consider that the mechanism of action of ETO differ to that of CBP because it is cell cycle specific. This is 
because ETO acts only in the G2 phase of the cell cycle, in particular when the enzyme Topoisomerase II is 
active.78 We showed that NE positively correlated with G2/M phase of the cell cycle. The fact that NE 
apparently induced apoptosis (p53, LPS) only in a small percentage of cells (~20%) but, on the other hand, 
killed 100% of cells after 24h, suggests that only cells in a particular phase of cell cycle may be sensitive to 
NE. A possible explanation of the fact that these cells cannot be rescued from ETO, is that they are sensitive 
to NE only when they are in G2 phase, i.e. when ETO is also active. This hypothesis deserves to be 
confirmed in further studies. 
The message of this work is that, in analogy with the immune system,47,79-82 neural and neuroendocrine 
factors should be considered as important hematopoietic regulators. It is probable that beside 
catecholamines many other factors may affect hematopoiesis. For example, it has been reported that 
substance P and neurokinin-A may induce both positive and negative hematopoietic regulators in bone 
marrow stroma.83
,84 These findings indicate, in fact, that the endogenous release of multiple hematopoietic 
regulators may be controlled by neural or neuroendocrine factors. We might be before the tip of an iceberg 
representing  a mechanism of hematopoietic regulation capable of transducing environmental information to 
the blood-forming system. This open new frontiers in the immunological field. A central question is whether 
the neural regulation of hematopoieisis plays any role in aplastic anemia, leukemia, immune-based diseases 
or during emergencies such as acute infections and/or stress events. Any positive answer to this question 
might provide a conceptual framework in which new pharmacological strategies to prevent or correct 
pathological situations could be devised. 
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